C Diff Treatment

Serious infections occurred in less than 2% of patients treated with the medication during the duration of the 52-week trial.

Patients hospitalized with CDI reported low scores on the Cdiff32 and PROMIS GH, demonstrating a negative impact of CDI on QoL in multiple health domains. The Cdiff32 questionnaire is particularly sensitive to QoL changes in patients with recurrent or severe disease.

Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The activity of omadacycline and five comparators was assessed w …

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (

Trials show a consistent efficacy profile and a consistent safety profile for RBX2660 in reducing the recurrence of C. difficile infection.

Just 7% of patients in the BPA group suffered a recurrent CDI episode within 14-56 days of initiating treatment.

Great Grand Rounds by Dr. Byron Vaughn-making sense of conflicting C. Difficile guidelines!-No single tests can replace clinical acumen-Recommend 2-step testing algorithm-Practical tip to distinguish colonization vs. CDI- consider fecal inflammatory markers#CDiff #GITwitter pic.twitter.com/zsCY24ER84— Lizzie Aby, MD (@LizzieAbyMD) September 30, 2021

Fidaxomicin-Prevents recurrent CDI-Early fidaxomicin is cost effective (PMID: 31001619), but barriers including insurance approval & cost#CDI #CDiff #GITwitter pic.twitter.com/Gmie4k8w8J— Lizzie Aby, MD (@LizzieAbyMD) September 30, 2021

The treatments for colitis will depend on the cause but can include medications and changes to diet. For some conditions, surgery might also be used.

Aimee Shen, associate professor of molecular biology & microbiology at Tufts University, will speak at the Virginia Tech Life Science Seminar (VTLSS) on Friday, October 1 at 12:00 p.m.

A teenage girl had the rare combined phenotype of xeroderma pigmentosum and trichothiodystrophy, resulting from mutations in the XPD (ERCC2) gene involved in nucleotide excision repair (NER). After treatment with antibiotics, including metronidazole for recurrent infections, she showed signs of acute and severe hepatotoxicity, which gradually resolved after withdrawal of the treatment. Cultured skin fibroblasts from the patient revealed cellular sensitivity to killing by metronidazole compared with cells from a range of other donors. This reveals that the metronidazole sensitivity was an intrinsic property of her cells. It is well recognized that patients with Cockayne syndrome, another NER disorder, are at high risk of metronidazole-induced hepatotoxicity, but this had not been reported in individuals with other NER disorders. We would urge extreme caution in the use of metronidazole in the management of individuals with the xeroderma pigmentosum and trichothiodystrophy overlap or trichothiodystrophy phenotypes.

Clostridioides difficile (C. difficile) is a spore-producing Gram-positive anaerobic bacterium and a leading cause of healthcare-associated infection. C. difficile is a commensal organism within the human intestinal flora found in up to 66% of newborn babies; colonisation rates drop over time and around 3% of healthy adults remain colonised​[1]​. Most colonised patients remain asymptomatic; however, […]

Clinical decision support increased prescribing of guideline-concordant CDI therapy in the outpatient setting. A targeted BPA is an effective stewardship intervention and may be especially useful in settings with limited antimicrobial stewardship resources.

The Infectious Diseases Society of America’s (IDSA) 2017 guideline saw an increase in using vancomycin as a first line therapy for Clostridioides difficile (CDI).

Are you up to date on the latest antimicrobial prescribing recommendations for C. difficile? Join us with @MAD_ID_ASP for a live, one-hour virtual, symposium on October 11th. Registration is free: https://t.co/Y2yBN5TI67 #cdiff #pharmacist #antimicrobial #virtualsymposium pic.twitter.com/FTlXxQm5Ht— ACHL (@achlcme) September 27, 2021

Thanks to ⁦@bwilson10233⁩ for dazzling us ⁦@UNC_ID⁩ with a great #cdiff treatment talk! 🌈💩 pic.twitter.com/MfrOnJWrcD— Claire Farel (@claire_farel) September 24, 2021

Living Your Best Life

Individuals in a study who received the food with BB-12 probiotic retained beneficial metabolites produced by the microbiota.

RT @PeggyFund: Please save the date for our 2021 virtual FIGHT C. DIFF Gala, to be held on Monday, November 1st at 8 pm EST. More details i…

2021 guidelines from the American Society of Colon and Rectal Surgeons, published in Diseases of the Colon and Rectum (also see reference)

#Cdiff Spores and More Live Broadcast to Podcast https://t.co/tWTyXNxBdd Guest Host: Kevin Hersh Welcomed the new tool available....For #Patients #families and #caregivers https://t.co/QtVwFElCbV#microbiome #clinicaltrials #gastroenterology #Cdifficile #healthcare #CDI pic.twitter.com/xQJOCVYprd— C DIFF FOUNDATION (@cdiffFoundation) September 15, 2021

New recommendations outlined include advice for managing C. difficile infection in both community and hospital settings

Ten quiz questions to assess your knowledge on common symptoms and treatments for Clostridioides difficile.

The study demonstrated administration of SoC + bezlotoxumab in patients at high risk of CDI recurrence is cost-saving from a hospital management perspective. Reduced length of stay in bezlotoxumab treated patients creates free spatial and personnel capacities for the treating hospital. Yet, a requir …